Medrx Co

Medrx Co Retained Earnings

The Retained Earnings of Medrx Co (4586.T) as of Nov 19, 2026 is -898.75 M JPY. In the previous year, Retained Earnings was -787.07 M JPY — a change of 14.19% (lower).

Retained Earnings

-898.75 MJPY

YoY

14.19%

Last updated:

Retained Earnings of Medrx Co is 2025 -898.75 M JPY. Retained Earnings of Medrx Co was 2024 -787.07 M JPY. It decreases by 14.19% lower compared to the previous year.

The Medrx Co Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
-9.49 B JPY
Jan 1, 2019
-11.11 B JPY
Jan 1, 2020
-12.22 B JPY
Jan 1, 2021
-13.28 B JPY
Jan 1, 2022
-2.15 B JPY
Jan 1, 2023
-915.00 M JPY
Jan 1, 2024
-787.07 M JPY
Jan 1, 2025
-898.75 M JPY
The Medrx Co Retained Earnings history
YEARRetained EarningsYoY
-898.75 MJPY+14.19%
-787.07 MJPY-13.98%
-915.00 MJPY-57.45%
-2.15 BJPY-83.81%
-13.28 BJPY+8.67%
-12.22 BJPY+10.04%
-11.11 BJPY+17.03%
-9.49 BJPY+15.42%
-8.22 BJPY+12.05%
-7.34 BJPY+20.72%
-6.08 BJPY+16.89%
-5.20 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Retained Earnings of Medrx Co is -898.75 M JPY in 2025.

Retained Earnings of Medrx Co changed from -787.07 M JPY to -898.75 M JPY, representing a 14.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Medrx Co since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medrx Co

All Key Metrics — Medrx Co